2026-03-06T23:24:38Z https://hama-med.repo.nii.ac.jp/oai

oai:hama-med.repo.nii.ac.jp:02000037 2023-12-22T04:07:50Z 1:11

Development of a simple and objective prognostication model for patients with advanced solid malignant tumors treated with immune checkpoint inhibitors: A pan-cancer analysis Sano, Asuka Inoue, Yusuke Kikuchi, Hirotoshi Fukuchi, Kensuke Funai, Kazuhito Imai, Atsushi Matsushita, Yuto Tamura, Keita Kitagawa, Masatoshi Miyake, Hideaki open access This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s11523-022-00911-z Background Systemic therapy using immune checkpoint inhibitors (ICIs) has recently become prevalent in the treatment of patients with various types of advanced cancers; however, difficulties are still associated with predicting the outcomes of patients receiving ICIs due to heterogenous responses to these agents. Therefore, the objective of the present study was to develop a prognostic model for advanced cancer patients treated with ICIs. Patients and methods This study retrospectively analyzed the impact of clinical parameters on overall survival (OS) in 329 patients with several advanced solid malignant tumors who received systemic therapy using ICIs. Results The primary tumors of 329 patients were as follows: lung (n=89), kidney (n=70), urinary tract (n=52), skin (n=50), stomach (n=30), esophagus (n=21), and head and neck (n=17). Median OS after the introduction of ICIs was 17.3 months. Among the factors that correlated with OS in a univariate analysis, body mass index, C-reactive protein, hemoglobin, lymphocytes, and platelets were identified as independent predictors of OS in a multivariate analysis. Following the classification of patients into 3 groups based on positive numbers of these independent risk factors, median OS was not reached in the favorable risk group with 0 or 1 risk factor (n=76), 19.5 months in the intermediate-risk group with 2 or 3 risk factors (n=182), and 8 months in the poor risk group (n=71) with 4 or 5 risk factors. Conclusions Although this is a simple and objective model, it may be used as a reliable tool to predict the outcomes of advanced cancer patients receiving ICIs across multiple tumor types. Springer Nature 2022-09 eng journal article AM http://hdl.handle.net/10271/0002000037 https://hama-med.repo.nii.ac.jp/records/2000037 36094602 https://doi.org/10.1007/s11523-022-00911-z 1776-2596 1776-260X AA12157617 Targeted Oncology 17 5 583 589 https://hama-med.repo.nii.ac.jp/record/2000037/files/Target Oncol-17-583.pdf application/pdf 409 KB 2023-11-29